
Providing essential Ig supplementation
across multiple indications
Connect with us
Meet with your CSL Behring Associate Director of
Corporate Accounts.
Meet with your CSL Behring Associate Director of Corporate Accounts.
Schedule a meetingAbout PI and CIDP
Primary immunodeficiency (PI) diseases occur in patients who have an intrinsic defect in the immune system. The immune system may have impaired function in one or more components or a component may be absent altogether.1 There are 485 different PIs currently recognized by the International Union of Immunological Societies Expert Committee—some are common, others are quite rare.2 Untreated patients are at increased risk of severe, persistent, and recurrent infection, which may occur at various locations throughout the body.3
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder of the peripheral nerves characterized by progressive weakness and a loss of sensory and motor function in the legs and arms. CIDP is a neurological disorder with an underlying autoimmune basis: the immune system perceives the nerves’ protective myelin as foreign and attacks it. Damaged or removed myelin prevents effective communication in the nervous system, as electric impulses transmitted to and from the brain are disrupted or lost.4
Privigen is an important part of CSL Behring’s portfolio of immunoglobulin (Ig) products.What is Privigen?
Privigen is an intravenous Ig (IVIg) replacement therapy indicated for the treatment of PI, chronic immune thrombocytopenic purpura (ITP) in patients aged ≥15 years, and CIDP in adults.
Privigen maintenance therapy in CIDP has not been studied for periods longer than 6 months. After responding during an initial treatment period, not all patients require indefinite maintenance therapy with Privigen in order to remain free of CIDP symptoms. Individualize the duration of any treatment beyond 6 months based upon the patient’s response and demonstrated need for continued therapy.
What are the key benefits?
For PI
PROVEN EFFICACY
The annual rate of serious bacterial infections (SBIs)* was 0.08 in the US phase 3 pivotal trial and 0.02 in the extension study5
For CIDP
RAPID RESPONSE
Almost all who responded† to Privigen did so after 1 to 2 maintenance treatments at Weeks 4 and 7.‡ Overall response rates to Privigen were 61% and 73% in PRIMA and PATH,‡ respectively†
*SBIs were defined as pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
†Overall response rate was defined as percentage of subjects who experienced at least a 1-point decrease in adjusted INCAT score.
‡In a prospective, open-label, single-arm, multicenter clinical study (PRIMA), 28 subjects with CIDP received a Privigen loading dose of 2 g/kg followed by Privigen maintenance doses of 1 g/kg every 3 weeks for up to 21 weeks with 3-week follow-up. In a second prospective, open-label Privigen prerandomization phase of a multicenter clinical study (PATH), 207 IVIg-pretreated subjects with CIDP received a Privigen loading dose of 2 g/kg followed by up to 4 Privigen maintenance doses of 1 g/kg every 3 weeks for up to 13 weeks.
INCAT=Inflammatory Neuropathy Cause and Treatment; PATH=Polyneuropathy and Treatment with Hizentra; PRIMA=Privigen Impact on Mobility and Autonomy.
The value of Privigen
CSL Behring is a class leader in IVIg treatments with a broad portfolio of Ig products
A TOP 3 IVIg IN US HOSPITALS
Privigen has been consistently in the top 3 in US hospitals since 20106§
§Based on volume share in the hospital segment as of Q4 2023.
Want to learn more?
Meet with your CSL Behring Associate
Director of Corporate Accounts.
Help us help you
Share your thoughts so we can further
tailor our content.